Second Genome Lands $42,600,000 Series B Financing Round

  • Feed Type
  • Date
    4/20/2016
  • Company Name
    Second Genome
  • Mailing Address
    341 Allerton Avenue South San Francisco, CA 94080 USA
  • Company Description
    Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders.
  • Website
    http://www.secondgenome.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $42,600,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will be used to further expand the Second Genome Microbiome Discovery Platform in a range of indications associated with barrier function, insulin sensitivity, and immune regulation. In addition, proceeds from the financing will be used to advance the clinical investigation of SGM-1019, a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in ulcerative colitis, through human proof-of-concept studies.
  • M&A Terms
  • Venture Investor
    Pfizer Venture Investments
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    Lifeforce Ventures
  • Venture Investor
    Mayo Medical Ventures
  • Venture Investor
    Advanced Technology Ventures
  • Venture Investor
    Morgenthaler Ventures
  • Venture Investor
    Seraph Group
  • Venture Investor
    Investor

Trending on Xconomy